Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS | Zendy

Peter S. Staats | Zendy; Thomas Yearwood | Zendy; Steven G. Charapata | Zendy; R. Presley | Zendy; Mark S. Wallace | Zendy; Michael G. ByasSmith | Zendy; Robert B. Fisher | Zendy; David A. Bryce | Zendy; Eugene A. Mangieri | Zendy; Robert R. Luther | Zendy; Martha Mayo | Zendy; Dawn McGuire | Zendy; David Ellis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS

Author(s) -

Peter S. Staats,

Thomas Yearwood,

Steven G. Charapata,

R. Presley,

Mark S. Wallace,

Michael G. ByasSmith,

Robert B. Fisher,

David A. Bryce,

Eugene A. Mangieri,

Robert R. Luther,

Martha Mayo,

Dawn McGuire,

David Ellis

Publication year - 2004

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.291.1.63

Subject(s) - medicine , placebo , anesthesia , morphine , refractory (planetary science) , opioid , cancer pain , visual analogue scale , adverse effect , population , cancer , physics , alternative medicine , receptor , environmental health , pathology , astrobiology

Ziconotide (formerly SNX-111) selectively blocks N-type voltage-sensitive calcium channels and may be effective in patients with pain that is refractory to opioid therapy or those with intolerable opioid-related adverse effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research